Investigational CDK4/6 Inhibitor Abemaciclib is Active Against a Range of Cancer Types
The investigational anticancer therapeutic abemaciclib (formerly LY2835219), which targets CDK4 and CDK6, showed durable clinical...
Fighting Cancer With Killer T-Cells
Three companies are locked in a tight race to develop next-generation immuno-oncology treatments called chimeric antigen receptor T-cells...
